Statement of the Problem: Paxillin (PXN) is one of the proteins involved in cell adhesion. PXN and integrins constitute a key site for the focal adhesion between the cell and extracellular matrix. Several studies have shown that PXN is a factor in tumor formation, progression, invasion, and metastasis.
Purpose: This study evaluated PXN expression in four types of odontogenic lesions with different aggressive behaviors.
Materials and Method: In this retrospective cross-sectional study, PXN expression was immunohistochemically assessed in 68 paraffin-embedded tissue samples from patients with the confirmed diagnosis of four types of odontogenic lesions, including 14 dentigerous cysts (DC), 20 odontogenic keratocyst (OKC), 16 unicystic ameloblastoma, and 18 solid ameloblastoma. The PXN expression in these samples were scored based on the percentage and intensity of immunoreactivity, and compared among the groups by Chi-square test.
Results: The PXN marker was detected in the cytoplasm of tumor cells (unicystic and solid ameloblastoma) and the epithelial layer of cysts (DC and OKC). The intensively stained marker of PXN was observed in 9 cases (64.3%) of the DC, 14 cases (70%) of OKC, 12 cases (75%) of unicystic ameloblastoma, and 13 cases (72.2%) of solid ameloblastoma. However, there was not statistical difference of PXN protein expression between DC and OKC (p Value = 0.51) and unicystic and solid ameloblastoma (p = 0.58), also the same was true for cysts and tumors (p = 0.37).
Conclusion: The expression of PXN is not related to the biological behaviors of odontogenic lesions. |
- Santosh AB. Odontogenic cysts. Dent Clin North Am. 2020; 64: 105-119.
- Ochsenius G, Escobar E, Godoy L, Peñafiel C. Odontogenic cysts: analysis of 2.944 cases in Chile. Med Oral Patol Oral Cir Bucal. 2007; 12: E85-E91.
- Santosh AB, Ogle OE. Odontogenic tumors. Dent Clin North Am. 2020; 64: 121-138.
- Sharifi-Sistani N, Zartab H, Babakoohi S, Saghravanian N, Jamshidi S, Esmaili H, et al. Immunohistochemical comparison of the expression of p53 and MDM2 proteins in ameloblastomas and keratocystic odontogenic tumors. J Craniofac Surg. 2011; 22: 1652-1656.
- Masthan KM, Anitha N, Krupaa J, Manikkam S. Ameloblastoma. J Pharm Bioallied Sci. 2015; 7(Suppl 1): S167-S170.
- Alves DB, Tuji FM, Alves FA, Rocha AC, Santos-Silva AR, Vargas PA, et al. Evaluation of mandibular odontogenic keratocyst and ameloblastoma by panoramic radiograph and computed tomography. Dentomaxillofac Radiol. 2018; 47: 20170288.
- Anand R, Narwal A, Pandiar D, Kamboj M, Devi A, Saxena S, et al. Clinicopathological profile of 80 cases of unicystic ameloblastoma aided by a histopathological comparison using modified Philipsen–Reichart classification and Marx–Stern classification. Head Neck Pathol. 2021; 15: 875-881.
- Song M, Hu J, Quan HY. Abnormal expression of FAK and paxillin correlates with oral cancer invasion and metastasis. Acta Biochim Pol. 2021; 68: 317-323.
- López-Colomé AM, Lee-Rivera I, Benavides-Hidalgo R, López E. Paxillin: a crossroad in pathological cell migration. J Hematol Oncol. 2017; 10: 50.
- Liu Z, Yang Z, Jiang S, Zou Q, Yuan Y, Li J, et al. Paxillin and carbonic anhydrase IX are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas. Histopathology. 2014; 64: 921-934.
- Sun LH, Yang FQ, Zhang CB, Wu YP, Liang JS, Jin S, et al. Overexpression of paxillin correlates with tumor progression and predicts poor survival in glioblastoma. CNS Neurosci Ther. 2017; 23: 69-75.
- Shekhar S, Angadi PV. Evaluation of paxillin expression in patients with oral squamous cell carcinoma: an immunohistochemical study. J Oral Maxillofac Pathol. 2017; 21: 318-319.
- Tanaka N, Minemura C, Asai S, Kikkawa N, Kinoshita T, Oshima S, et al. Identification of miR-199-5p and miR-199-3p target genes: Paxillin facilities cancer cell aggressiveness in head and neck squamous cell carcinoma. Genes (Basel). 2021; 12: 1910.
- Andisheh-Tadbir A, Afshari A, Ashraf MJ. Expression of Paxillin in Benign and Malignant Salivary Gland Tumors. J Dent (Shiraz). 2019; 20: 249-254.
- Ma X, Hammes SR. Paxillin actions in the nucleus. Steroids. 2018; 133: 87-92.
- Wu DW, Huang CC, Chang SW, Chen TH, Lee H. Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. Cell Death Differ. 2015; 22: 779-789.
- Shi J, Wang S, Zhao E, Shi L, Xu X, Fang M. Paxillin expression levels are correlated with clinical stage and metastasis in salivary adenoid cystic carcinoma. J Oral Pathol Med. 2010; 39: 548-551.
- Panetti TS. Tyrosine phosphorylation of paxillin, FAK, and p130CAS: effects on cell spreading and migration. Front Biosci. 2002; 7: d143-d150.
- Kandelman JD, Waitzberg AF, Szejnfeld J, Smith RL. Expression of claudin, paxillin and FRA-1 in non-nodular breast lesions in association with microcalcifications. Sao Paulo Med J. 2013; 131: 71-79.
- Madan R, Smolkin MB, Cocker R, Fayyad R, Oktay MH. Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma. Hum Pathol. 2006; 37: 9-15.
- Bello IO, Alrabeeah MA, AlFouzan NF, Alabdulaali NA, Nieminen P. FAK, paxillin, and PI3K in ameloblastoma and adenomatoid odontogenic tumor. Clin Oral Investig. 2021; 25:1559-1567.
- Baz S, Mohamed S. Double Immunohistochemical Analysis of PCNA and FAK Expression in Selected Odontogenic Lesions. Egyptian Dent J. 2023; 69: 1129-1138.
- Lin CW, Sun MS, Liao MY, Chung CH, Chi YH, Chiou LT, et al. Podocalyxin-like 1 promotes invadopodia formation and metastasis through activation of Rac1/ Cdc42/ cortactin signaling in breast cancer cells. Carcinogenesis. 2014; 35: 2425-2435.
|
